James F. Oliviero III Sells 24,610 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Stock

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO James F. Oliviero III sold 24,610 shares of the business’s stock in a transaction that occurred on Wednesday, June 26th. The shares were sold at an average price of $2.05, for a total transaction of $50,450.50. Following the sale, the chief executive officer now owns 1,977,170 shares of the company’s stock, valued at $4,053,198.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Checkpoint Therapeutics Price Performance

Shares of NASDAQ:CKPT traded up $0.09 during mid-day trading on Friday, reaching $2.15. 252,621 shares of the company traded hands, compared to its average volume of 477,131. The company’s 50 day moving average price is $1.78 and its 200-day moving average price is $1.93. The firm has a market cap of $76.73 million, a PE ratio of -0.78 and a beta of 1.13. Checkpoint Therapeutics, Inc. has a 52 week low of $1.30 and a 52 week high of $3.62.

Checkpoint Therapeutics (NASDAQ:CKPT) last released its earnings results on Friday, May 10th. The company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.04. On average, research analysts predict that Checkpoint Therapeutics, Inc. will post -1.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Checkpoint Therapeutics

Several large investors have recently added to or reduced their stakes in CKPT. Tower Research Capital LLC TRC lifted its holdings in Checkpoint Therapeutics by 92.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 11,174 shares of the company’s stock valued at $26,000 after purchasing an additional 5,375 shares in the last quarter. Choreo LLC purchased a new position in Checkpoint Therapeutics during the fourth quarter valued at approximately $44,000. Magnus Financial Group LLC purchased a new position in Checkpoint Therapeutics during the fourth quarter valued at approximately $55,000. Lindbrook Capital LLC purchased a new position in Checkpoint Therapeutics during the first quarter valued at approximately $62,000. Finally, B. Riley Wealth Advisors Inc. lifted its holdings in Checkpoint Therapeutics by 9.4% during the third quarter. B. Riley Wealth Advisors Inc. now owns 49,150 shares of the company’s stock valued at $84,000 after purchasing an additional 4,205 shares in the last quarter. Hedge funds and other institutional investors own 22.00% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $34.00 price target on shares of Checkpoint Therapeutics in a research note on Monday. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, Checkpoint Therapeutics has an average rating of “Buy” and a consensus price target of $22.60.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.